An interventional study of J-VALVE Transfemoral Aortic Valve system and Commercially available surgical biological aortic valve replacement device in Aortic Regurgitation, Aortic Valve Insufficiency and Aortic Insufficiency, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 28 sites in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Aortic Valve Insufficiency with a site in China — 17 open to participants now, 17 under way, none of them phase 3. Aortic Valve Insufficiency · China.
Among the 23 studies in Aortic Valve Insufficiency with a site in China, this one has the largest planned enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2026, is one of 10 with no phase, reaches primary completion later than 11 of the 16 other live ones, and was the 17th registered.
171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.
Browse Aortic Valve Insufficiency studies →17 of the 23 studies in Aortic Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Anhui Provincial Cancer Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Mitrassist Lifesciences Limited Co., Ltd. · Sites in China
Ages 50+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 60+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,250 is above the median of 123 across 92 interventional studies indexed under Aortic Valve Insufficiency.
Median enrollment 116 across the 11 interventional studies, 3,750 across the 12 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 23 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 108 studies on the registry; 73 are open to participants now.
Second Affiliated Hospital, Zhejiang University, School of Medicine has 1 study filed under Aortic Valve Insufficiency — fewer than ten, so there is no comparison to draw.
2 of the studies in Aortic Valve Insufficiency with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07453849Chinese Academy of Medical Sciences, Fuwai HospitalTAVR for Aortic Regurgitation Under TEE Guidance | 2026-12-31 |
| NCT06818084Ruijin HospitalTRanscAtheter TreatMent of PurE Aortic Regurgitation With VitaFlow Liberty System | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Aortic Valve Insufficiency with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall purpose of ART trial is to establish the Safety and Efficacy of the J-VALVE Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Patients with Grade≥3+ Native Aortic Regurgitation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
2) a. Symptomatic patients with severe AR b. Asymptomatic patients with severe AR and evidence of LV function impairment (per current ESC / ACC guidelines) Any of the following perimeters
Exclusion Criteria:
9. Anatomical exclusion criteria (ANY of the following):
18. Complex coronary artery disease (one of the following):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transcatheter aortic valve replacement (TAVR) using J-VALVE Transfemoral Aortic Valve system
Device: J-VALVE Transfemoral Aortic Valve system
Surgical aortic valve replacement(SAVR)using commercially available surgical biological aortic valve replacement device
Device: Commercially available surgical biological aortic valve replacement device
Transcatheter aortic valve replacement (TAVR) using J-VALVE Transfemoral Aortic Valve system
Surgical aortic valve replacement(SAVR)using commercially available surgical biological aortic valve replacement device
All-cause mortality
All-cause mortality at 12 months
Time frame: 12 months
All stroke
Number of patients with stroke
Time frame: 12 months
Unplanned cardiac rehospitalization
Number of patients who had unplanned cardiac rehospitalization
Time frame: 12 months
New-onset atrial fibrillation
Comparing the onset of atrial fibrillation in TAVR with SAVR
Time frame: 30 days
Echocardiographic effective orifice area
Comparing echocardiographic effective orifice area in TAVR with SAVR
Time frame: 30 days
Moderate or greater patient prosthesis mismatch as measured by echocardiography
Comparing moderate or greater patient prosthesis mismatched in TAVR with SAVR
Time frame: 30 days
Cardiovascular rehospitalization
Comparing the number of cardiovascular rehospitalizations in TAVR with SAVR
Time frame: 30 days
Health-related quality of life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ-23)
Comparing change in KCCQ-23 in TAVR with SAVR. The KCCQ score ranges from 0 to 100, with higher scores indicating better quality of life.
Time frame: 30 days
Length of index hospitalization
Comparing TAVR length of index hospitalization with SAVR
Time frame: Pre-intervention/procedure surgery
Composite primary endpoints
Comparing the superiority of the composite primary endpoint and its components in TAVR with SAVR
Time frame: 30 days
Bleeding complications (life-threatening, disabling, or major)
Comparing bleeding complications in TAVR with SAVR
Time frame: 30 days, 6 months and 1 year
Major adverse cardiovascular and cerebrovascular events (MACCE)
Freedom of major adverse cardiovascular and cerebrovascular events
Time frame: years 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Mortality (all-cause & cardiovascular)
Comparing mortality (all-cause \& cardiovascular in TAVR with SAVR
Time frame: 30 days,6 months and years 1, 5, 10
Stroke (disabling and nondisabling)
Comparing stroke (disabling and nondisabling) in TAVR with SAVR
Time frame: 30days, 6 months and years 1, 5, 10
Death or stroke
Comparing death or stroke in TAVR with SAVR
Time frame: 1 year
Death or disabling stroke
Comparing death or disabling strokein TAVR with SAVR
Time frame: 30 days, and 1 year
Major vascular complications
Comparing major vascular complications in TAVR with SAVR
Time frame: 30 days
Other procedural or valve-related complications
Comparing other procedural or valve-related complications in TAVR with SAVR
Time frame: 30 days
Technical success
Comparing technical success in TAVR with SAVR
Time frame: Exit from procedure room
Device success
Comparing device success in TAVR with SAVR
Time frame: 30 days
Myocardial infarction
Comparing myocardial infarction in TAVR with SAVR
Time frame: 30 days, 6 months and 1 year
Coronary obstruction requiring intervention
Comparing coronary obstruction requiring intervention in TAVR with SAVR
Time frame: 30 days, 6 months and 1 year
Acute kidney injury
Comparing acute kidney injury in TAVR with SAVR
Time frame: 30 days
Renal replacement therapy
Comparing renal replacement therapy in TAVR with SAVR
Time frame: 1 year
New permanent pacemaker implantation
Comparing new permanent pacemaker implantation in TAVR with SAVR
Time frame: 30 days, 6 months and years 1, 5, 10
Conduction disturbance and arrhythmias
Comparing conduction disturbance and arrhythmias in TAVR with SAVR
Time frame: 30 days,6 months and 1 year
New York Heart Association class
Comparing change in New York Heart Association class in TAVR with SAVR
Time frame: 30 days, 6 months and years 1, 5, and 10
Hemodynamic valve performance evaluated by echocardiography
Comparing hemodynamic valve performance evaluated by echocardiography in TAVR with SAVR
Time frame: 30 days, 6 months and at years 1, 2, 3, 4, 5, 7, 10.
Other echocardiographic parameters
Comparing other echocardiographic parameters in TAVR with SAVR
Time frame: 30 days, and years 1, 2, 3, 4, 5, 7, 10.
Cardiovascular rehospitalization
Comparing cardiovascular rehospitalizations( the time to first event and number of events) in TAVR with SAVR
Time frame: 30 days, 6 months,1 year, and annually until 10 years
ICU days
Comparing ICU days in TAVR with SAVR
Time frame: Time from immediate post-operation to ICU discharge
Redo valve replacement
Comparing redo valve replacement in TAVR with SAVR
Time frame: 30 days, 6 months,1 year, and annually until 10 years
Six-minute walk test
Comparing change in six-minute walk test in TAVR with SAVR
Time frame: 30 days,6 months, and 1year
Health-related Quality of Life as Assessed by KCCQ-23
Comparing change in KCCQ-23 in TAVR with SAVR.The KCCQ score ranges from 0 to 100, with higher scores indicating better quality of life.
Time frame: 30days,6 months,1 year
Early safety
Comparing early safety in TAVR with SAVR
Time frame: 30 days
Clinical efficacy
Comparing clinical efficacy in TAVR with SAVR
Time frame: 1 year, and annually until 10 years
Valve related long-term clinical efficacy
Comparing valve related long-term clinical efficacy in TAVR with SAVR
Time frame: 5 years and thereafter until 10 years
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.
Of 44 interventional studies with no phase under Aortic Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 74. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, Zhejiang University, School of Medicine →